NASDAQ:SYNHSyneos Health Stock Price, Forecast & News

Syneos Health's stock was trading at $57.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYNH shares have increased by 4.2% and is now trading at $59.73. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syneos Health.

Syneos Health is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Syneos Health.

Syneos Health Inc (NASDAQ:SYNH) released its quarterly earnings data on Thursday, April, 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.64 by $0.04. The business earned $1.16 billion during the quarter, compared to analysts' expectations of $1.14 billion. Syneos Health had a net margin of 4.13% and a return on equity of 10.33%. Syneos Health's quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 earnings per share. View Syneos Health's earnings history.

11 equities research analysts have issued 1-year price targets for Syneos Health's shares. Their forecasts range from $42.00 to $82.00. On average, they expect Syneos Health's stock price to reach $60.45 in the next year. This suggests a possible upside of 1.2% from the stock's current price. View analysts' price targets for Syneos Health.

Media headlines about SYNH stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Syneos Health earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutSyneos Health.

Syneos Health saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,030,000 shares, an increase of 5.1% from the April 30th total of 5,740,000 shares. Based on an average trading volume of 812,200 shares, the short-interest ratio is presently 7.4 days. Approximately 9.7% of the company's stock are sold short. View Syneos Health's Current Options Chain.

Some companies that are related to Syneos Health include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), PRA Health Sciences (PRAH), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF) and Luna Innovations (LUNA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Square (SQ), AT&T (T), CVS Health (CVS), Gilead Sciences (GILD), UnitedHealth Group (UNH), Visa (V) and Delta Air Lines (DAL).

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Syneos Health's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.18%), Clearbridge Investments LLC (3.37%), ArrowMark Colorado Holdings LLC (2.32%), Mackenzie Financial Corp (2.15%), State Street Corp (1.90%) and JPMorgan Chase & Co. (1.79%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs, Jonathan Olefson, Michelle Keefe, Paul Colvin and Robert Parks. View institutional ownership trends for Syneos Health.

SYNH stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Mackenzie Financial Corp, BlackRock Inc., Principal Financial Group Inc., Clearbridge Investments LLC, Nuveen Asset Management LLC, Magnetar Financial LLC, and Bank of New York Mellon Corp. Company insiders that have sold Syneos Health company stock in the last year include Michelle Keefe, and Robert Parks. View insider buying and selling activity for Syneos Health.

SYNH stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., ArrowMark Colorado Holdings LLC, JPMorgan Chase & Co., AQR Capital Management LLC, Massachusetts Financial Services Co. MA, Geode Capital Management LLC, and Mutual of America Capital Management LLC. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs, Jonathan Olefson, and Paul Colvin. View insider buying and selling activity for Syneos Health.

Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYNH stock can currently be purchased for approximately $59.73.

Syneos Health has a market capitalization of $6.22 billion and generates $4.68 billion in revenue each year. The company earns $131.26 million in net income (profit) each year or $2.83 on an earnings per share basis. Syneos Health employs 24,000 workers across the globe.

The official website for Syneos Health is www.syneoshealth.com.

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The company can be reached via phone at 919-876-9300 or via email at [email protected]